Abstract
IT IS FAIR TO SAY the pharmaceutical industry faces the kind of dilemma that leaves it little choice other than to implement fundamental change. Its reversal of fortune since the 1980s and '90s can be measured in the drop in the number of significant new drugs coming to market, increased threats to profitability, and a nearly heroic fall from grace in public opinion as a result of concerns over the safety and price of drugs. It is also obvious that big changes are under way, given the raft of plant closures, staff reductions, and top management departures in recent years. It is a familiar scenario. Much of what is taking place is reminiscent of the reengineering wave that hit almost every other major industrial sector, including computers, automotive, and chemicals, about 10 years ago. From my point of view, the real world has caught up with the pharmaceutical industry, says Michael ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
